NGS-based In Vitro Diagnostics

In 2015 and 2016, ASHG submitted comments to the U.S. Food and Drug Administration (FDA) on two related proposed regulations for Next Generation Sequencing (NGS)-based in vitro diagnostics. Appreciative of being engaged in the process, ASHG submitted comments to further inform and clarify the issue.


ASHG uses cookies to provide you with a secure and custom web experience. Privacy Policy